IBRX Oct 2026 6.500 put (IBRX261030P00006500) Stock Price, News, Quote & History

Jim Cramer Calls Celsius 'A Second-Rate Monster,' Says Stick With the Original

IBRX Oct 2026 3.500 call (IBRX261030C00003500) Stock Price, News, Quote & History

IBRX Stock Rises Overnight: Jim Cramer Backs ImmunityBio As A ‘Very Good Spec’ Amid Biotech Takeover Wave

Is HeartSciences Inc. (HSCS) Stock Outpacing Its Medical Peers This Year?

ImmunityBio Locks Anktiva Trial Database, Eyes November Results As FDA Filing Nears

ImmunityBio Announces Database Lock for Registrational Trial of Locally Delivered, Chemotherapy-Free ANKTIVA® Plus BCG in BCG-Naïve Non-Muscle Invasive Bladder Cancer

ImmunityBio Anticipates Reporting Topline Results In November 2026, Remains On Track To Submit sBLA To FDA In Q4 2026 For ANKTIVA Plus BCG In Patients With BCG-Naïve NMIBC

ImmunityBio Completes Database Lock For Cohort A Of QUILT-2.005, Randomized, Controlled, Registrational Trial Evaluating ANKTIVA In Combination With BCG Versus BCG Alone In Patients With BCG-Naïve NMIBC

9 Health Care Stocks Whale Activity In Today’s Session

ANKTIVA Label Expansion Could Change The Case For ImmunityBio Stock

ImmunityBio Study Shows Long-Term Success for Bladder Cancer Treatment

ImmunityBio: Not Executing At The Level That The Market Is Pricing In

ImmunityBio Reports Phase 3 Data Showing 84% Cystectomy Avoidance at Three Years and Complete Responses Beyond 53 Months with ANKTIVA® Plus BCG in BCG-Unresponsive NMIBC With CIS, With or Without Papillary Tumors

FDA Expands ANKTIVA® Approval for BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer to Cover Both Papillary and CIS Disease